About Eligo Bioscience
Eligo Bioscience is the world leader in microbiome in-vivo gene editing and is advancing a highly differentiated pipeline of precision medicines to address unmet medical needs in immunoinflammation, oncology, and infectious diseases driven by the expression of deleterious bacterial genes. Eligo was founded by Luciano Marraffini (Professor at The Rockefeller University and cofounder of Intellia Therapeutics, Timothy Lu (Professor at MIT, and CEO at Senti Biosciences), Dr. David Bikard (Professor at Institut Pasteur) and Xavier Duportet (MIT TR35, Young Global Leader, and Termeer Fellow). Eligo was named a Technology Pioneer by the World Economic Forum and received venture capital funding from Sanofi Ventures, Khosla Ventures, BPI France, and Seventure Partners.
- Founding: 2014
- Focus : Manufacturer
- Employees: 11-50
- Industry : Biotechnology
Advertisement
Here you will find Eligo Bioscience
Last viewed contents
Heqet Therapeutics - Torino, Italy
Merck Life Science KGaA - Darmstadt, Germany
StratifAI Raises €12.5M for Clinical Validation of AI Biomarker Platform for Precision Oncology - Oversubscribed round expand global reach, and unlock multi‑billion‑euro cancer diagnostics market
Simply taste your way to flu infection - Rapid test for influenza viruses using chewing gum – without the need for a laboratory, electricity or medical personnel
Transparent artificial intelligence improves assessment of prostate cancer aggressiveness - AI speaks the language of pathologists
New nanosensors make diagnostic procedures more sensitive - The nanosensors can be used to track reactions with invisible light, saving materials and time
Cyber Valley grants 500K to CELL’n’ROLL via 2023 Innovation Fellowship Program - Cyber Valley Community is advancing diagnostics for the future: Its goal is to create an innovative spin-off from the project after the funding term has ended
Blood diagnostics modelled on leeches - For all those who are afraid of needles: New device for taking blood samples uses microneedles and a suction cup instead of a large needle
AI personalises brain tumour therapy - Progress in the personalised treatment of brain tumours: AI identifies mutations
En Carta Diagnostics secures €1.5M to advance diagnostic kit platform for early Lyme disease detection - Groundbreaking patented molecular diagnostic kit poised to provide game-changing autonomous Lyme detection in minutes
Portable AI-based test kit to identify bacterial infections - Dutch scientist selected as a finalist for the Young Inventors Prize 2024: Her startup focuses on the most common types of infection
